Loading…
Maker of food safety and animal health testing products, including diagnostics, genomics and sanitation solutions.
Maker of food safety and animal health testing products, including diagnostics, genomics and sanitation solutions.
Sells test kits and the readers that go with them, so most income is repeat purchases of single-use kits as customers test every batch of product. The 2022 combination with 3M's food-safety business greatly enlarged it and brought debt and integration work.
Moat: narrow (regulatory licence, switching costs, brand). Established brand and regulatory-validated test kits embedded in customers' food-safety and farm workflows.
Headquarters: Lansing, Michigan · Founded: 1982 · Employees: 2,636
Size Neogen (NEOG) is a United States Health Care company (Medical Specialties) with a market value of $2.57B, the 1637th largest of 3,117 United States companies the cockpit tracks. Shares closed at $11.76 on 6 Nov 2026.
Performance Over six months the shares gained 29.9%, against -0.6% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 0.3% over the last twelve months (peer median +7.7%); the operating margin is 0.0% (peer median 11.2%).
Valuation It trades at 34.6× forward earnings against a peer median of 27.5× (8th most expensive of 19).
Capital Return on invested capital runs 12.1 points below its cost of capital (12.1% WACC).
Short interest Short interest is 5.5% of the free float (15 Oct 2026).
Next results Next results expected around 14 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $884M | $870M | $895M | $924M | $822M |
| Revenue growth | — | -3% | -3% | +12% | — |
| Gross profit | $327M | $408M | $421M | $463M | $406M |
| EBITDA | $118M | $107M | $135M | $199M | $126M |
| Net income | -$56.1M | -$7.90M | -$1.09B | -$9.42M | -$22.9M |
| Free cash flow | $49.7M | $31.9M | -$48.4M | -$76.7M | -$24.7M |
| Capital expenditure | $35.5M | $51.3M | $105M | $111M | $65.8M |
| Total debt | $774M | $812M | $913M | $906M | $898M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Neogen NEOG | $2.57B | +30% | 0% | 0% | 34.6× | n/a |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Idexx Laboratories IDXX | $53.3B | +21% | +12% | 32% | 41.5× | 28.0% |
| Bio-Rad Laboratories BIO | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% |
| Zoetis ZTS | $32.8B | -4% | +1% | 38% | 12.8× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEOG | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.4% | +7.4% | 9th lowest of 21 |
| 6-month return | +29.9% | -0.6% | 4th highest of 21 |
| Distance from 52-week high | -17.5% | -32.2% | 8th highest of 21 |
| Revenue growth (TTM) | -0.3% | +7.7% | 4th lowest of 20 |
| Operating margin | 0.0% | 11.2% | 4th lowest of 20 |
| Forward P/E | 34.6× | 27.5× | 8th most expensive of 19 |
| ROIC minus cost of capital | -12.1 pp | -0.4 pp | 3rd lowest of 20 |
| EV / EBITDA | 26.9× | 16.9× | 5th most expensive of 11 |
| Net debt / EBITDA | 5.1× | -0.2× | most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Neogen NEOG | United States | $2.57B | +30% | 0% | 0% | 34.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.56B | -3% | +13% | 26% | 25.9× | 8.3% | +10.4% |
| Medacta MOVE.SW | Switzerland | $2.61B | -21% | +8% | 15% | 24.3× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.52B | +1% | +3% | 3% | 15.2× | 4.3% | +6.8% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.46B | +3% | +6% | 18% | 29.0× | 12.8% | +19.2% |
| Jafron Biomedical 300529.SZ | China | $2.46B | +8% | +1% | 37% | 25.4× | 6.9% | +0.6% |
| Elekta EKTA-B.ST | Sweden | $2.37B | +8% | -7% | 6% | 15.1× | 10.0% | +4.0% |
| COMET COTN.SW | Switzerland | $2.84B | -9% | -3% | 6% | 34.0× | n/a | n/a |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.27B | -27% | +8% | 29% | 22.1× | -1.6% | +14.1% |
| Metall Zug METN.SW | Switzerland | $2.25B | +19% | 0% | -10% | 139.2× | n/a | n/a |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 182.6× | n/a | n/a |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 220.7× | 55.7% | +20.9% |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 76.5× | 48.8% | +14.9% |
| Bonesupport BONEX.ST | Sweden | $2.16B | +34% | +25% | 25% | 61.9× | 13.3% | +45.4% |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 48.5× | 35.6% | +88.2% |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |